Table 3.

Technical and logistic consideration for serological testing in recipients of COVID-19 vaccination.

1.Prefer immunoassays detecting antibodies targeting the SARS-CoV-2 trimeric spike glycoprotein conformation, its S1(/S2) subunit, or its RBD;

2.Use methods that generate quantitative measures;

3.Always use the same method for the longitudinal monitoring of anti-SARS-CoV-2 antibodies’ kinetics;

4.Prefer laboratory-based assessment.